Literature DB >> 8116575

Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells.

C P Minniti1, M Tsokos, W A Newton, L J Helman.   

Abstract

Insulin-like growth factor II (IGF-II) acts as autocrine growth and motility factor in human rhabdomyosarcoma cell lines, and Northern blot analysis of tumor biopsy specimens from both alveolar and embryonal rhabdomyosarcoma demonstrates high levels of IGF-II mRNA expression. To determine the frequency and site of expression of IGF-II in these tumors, the authors performed in situ hybridization. All tumor specimens examined expressed the gene for IGF-II, and this expression was localized to the tumor cells themselves and not to the surrounding stroma. These data suggest that the IGF-II autocrine loop may be operating not only in vitro but also in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8116575     DOI: 10.1093/ajcp/101.2.198

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  21 in total

Review 1.  Advances in pediatric rhabdomyosarcoma characterization and disease model development.

Authors:  D O'Brien; A G Jacob; S J Qualman; D S Chandler
Journal:  Histol Histopathol       Date:  2012-01       Impact factor: 2.303

2.  Stress-induced isoforms of MDM2 and MDM4 correlate with high-grade disease and an altered splicing network in pediatric rhabdomyosarcoma.

Authors:  Aishwarya G Jacob; Dennis O'Brien; Ravi K Singh; Daniel F Comiskey; Robert M Littleton; Fuad Mohammad; Jordan T Gladman; Maria C Widmann; Selvi C Jeyaraj; Cheryl Bolinger; James R Anderson; Donald A Barkauskas; Kathleen Boris-Lawrie; Dawn S Chandler
Journal:  Neoplasia       Date:  2013-09       Impact factor: 5.715

Review 3.  Genomic imprinting and cancer.

Authors:  J A Joyce; P N Schofield
Journal:  Mol Pathol       Date:  1998-08

4.  Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy.

Authors:  Hemant K Bid; Cheryl A London; Jin Gao; Haihong Zhong; Robert E Hollingsworth; Soledad Fernandez; Xiaokui Mo; Peter J Houghton
Journal:  Clin Cancer Res       Date:  2013-04-02       Impact factor: 12.531

5.  Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma.

Authors:  Jinu Abraham; Suresh I Prajapati; Koichi Nishijo; Beverly S Schaffer; Eri Taniguchi; Aoife Kilcoyne; Amanda T McCleish; Laura D Nelon; Francis G Giles; Argiris Efstratiadis; Robin D LeGallo; Brent M Nowak; Brian P Rubin; Suman Malempati; Charles Keller
Journal:  Mol Cancer Ther       Date:  2011-03-29       Impact factor: 6.261

6.  Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2.

Authors:  Hemant K Bid; Jun Zhan; Doris A Phelps; Raushan T Kurmasheva; Peter J Houghton
Journal:  Mol Cancer Ther       Date:  2011-12-21       Impact factor: 6.261

7.  Insulin-like growth factor-1 and childhood cancer risk.

Authors:  Mohamed Badr; Tamer Hassan; Shereen El Tarhony; Wael Metwally
Journal:  Oncol Lett       Date:  2010-09-08       Impact factor: 2.967

8.  Systematic analysis of the TGF-beta/Smad signalling pathway in the rhabdomyosarcoma cell line RD.

Authors:  Hua Wang; Guang-Hua Yang; Hong Bu; Qiao Zhou; Li-Xin Guo; Shou-Li Wang; Lv Ye
Journal:  Int J Exp Pathol       Date:  2003-06       Impact factor: 1.925

9.  The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.

Authors:  Raushan T Kurmasheva; Lorina Dudkin; Catherine Billups; Larisa V Debelenko; Christopher L Morton; Peter J Houghton
Journal:  Cancer Res       Date:  2009-09-29       Impact factor: 12.701

10.  Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling.

Authors:  Wessen Maruwge; Pádraig D'Arcy; Annika Folin; Slavica Brnjic; Johan Wejde; Anthony Davis; Fredrik Erlandsson; Jonas Bergh; Bertha Brodin
Journal:  Onco Targets Ther       Date:  2008-11-01       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.